February 6, 2017
CMIC HOLDINGS Co., Ltd.
OrphanPacific, Inc.
Announcement of sales transfer of DIAZOXIDE Capsules 25 mg “MSD”
CMIC HOLDINGS Co., Ltd. (Headquarters: Minato-ku, Tokyo, Chairman & CEO: Kazuo Nakamura) has entered into an agreement with an affiliated company of MSD K.K. (Headquarters: Chiyoda-ku, Tokyo, Representative Director and President: Jannie Oosthuizen) regarding domestic sales of DIAZOXIDE Capsules 25 mg “MSD” in Japan.
Under this agreement, OrphanPacific, Inc. (Headquarters: Minato-ku, Tokyo, President, Representative Director: Philippe Auvaro, hereinafter referred to as “OrphanPacific”), a joint venture between CMIC HOLDINGS Co., Ltd. and MEDIPAL HOLDINGS CORPORATION, will sell the product, and provide and collect product information of DIAZOXIDE Capsules 25 mg “MSD”, as a distributor from April 1, 2017.
DIAZOXIDE Capsules 25 mg “MSD” is the only medicine in Japan that has been approved for the indication of “hyperinsulinemic hypoglycemia” associated with congenital hyperinsulinemia, insulinoma, and other condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose.
By supplying this product, OrphanPacific would further contribute to the treatment of pediatric metabolic and endocrine diseases, which is one of the focus areas of OrphanPacific.
[Contact departments of inquiries for this announcement]
CMIC HOLDINGS Co., Ltd.
PR Group, Corporate Communication Department Tel: 03-6779-8200
OrphanPacific, Inc.
Corporate Planning Department Tel: 03-6779-8151
